China Shineway Pharmaceutical Group is an investment holding company. Via its subsidiaries, Co. is engaged in the research and development, manufacture and trading of Chinese pharmaceutical products. Co.'s six key products include Qing Kai Ling Injection for treatment of viral diseases including respiratory tract infection, Shen Mai Injection for treatment of coronary heart disease, Shu Xie Ning Injection for treatment of cardio-cerebrovascular disease, Wu Fu Xin Nao Qing Soft Capsule for treatment of coronary heart disease, Huo Xiang Zheng Qi Soft Capsule for prevention and treatment of heat stroke,and Pediatric Qing Fei Hua Tan Granule for children infected by respiratory related disease.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.